NFKB1 and cancer: Thus, despite the clinical results obtained by targeting upstream NF-κB signaling mechanisms in the treatment of many B-cell tumors, the clinical benefits of this strategy have been limited by dose-limiting toxicities, the primary resistance of certain cancer types, and the relatively early onset of secondary drug resistance.